Image courtesy of Gamma Medica
December 4, 2014 — Gamma Medica announced a new strategic partnership with Volpara Solutions. By using these technologies together physicians can implement screening protocols based on a woman’s breast density and individual risk factors.
Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of mammography and therefore may impact early detection. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as dense tissue masks the appearance of tumors (Boyd et al 2007, NEJM). The measurement of breast density has conventionally relied on visual assessment by a radiologist.
VolparaDensity generates an objective, automatic measurement of volumetric breast density to help radiologists assess breast density objectively and Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system is a highly sensitive secondary diagnostic tool that can detect lesions as small as five millimeters. ProMedica Breast Care Center at Toledo Hospital is using both technologies to support a new imaging protocol to improve breast cancer screening for women with dense breasts.
While breast MRI is often indicated for high risk women, nearly 75 percent of women diagnosed with cancer do not have a family history. The LumaGEM MBI system is a supplemental screening tool when screening mammography is inconclusive, such as in women with dense breast tissue or for high risk women who cannot have a MRI.
For more information: www.gammamedica.com
February 04, 2026 
